Detalhe da pesquisa
1.
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
J Vasc Interv Radiol
; 33(9): 1034-1044.e29, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35526675
2.
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Eur J Haematol
; 92(2): 127-36, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24118452
3.
Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
BMC Nephrol
; 15: 71, 2014 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24885942
4.
Radiopaque drug-eluting embolisation beads as fiducial markers for stereotactic liver radiotherapy.
Br J Radiol
; 95(1130): 20210594, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34762499
5.
VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies.
JMIR Res Protoc
; 8(10): e13696, 2019 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31579027
6.
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
Drug Des Devel Ther
; 9: 2687-94, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26028965
7.
Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia.
Int J Hematol
; 100(4): 353-60, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25160063